Chronic accumulation of beta-amyloid in the brain has been shown to result in complex molecular and cellular changes that accompany neurodegeneration in Alzheimer's disease (AD). In this study, we examined the expression of a newly identified beta-secretase, memapsin 2 (M2) or beta-site APP cleaving enzyme in deparaffinized sections from 10 AD patients and 10 aged matched controls and in frozen samples of parietal cortex from 11 AD and 8 controls. M2 is mainly expressed in neurons, with high levels in CA4 to CA2 regions and transentorhinal cortex and low or intermediate levels in CA1, subiculum, and granule cells of the dentate gyrus. The majority of AD brains showed an increase of M2 expression in the CA1, but a decrease in the transentorhinal cortex. A subset of controls and AD patients had high M2 expression in parietal neocortex. Double-staining revealed that senile plaques are not directly associated with the soma of M2-expressing neurons. Neurofibrillary tangles were associated with lower M2 expression in AD. These data indicate that beta-secretase M2 may not be straightforwardly involved in amyloid plaque formation in AD brain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/exnr.2002.7875 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small molecule inhibits BACE1 activity by a dual mechanism confirmed by simulations-based study.
J Biomol Struct Dyn
December 2024
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India.
Article Synopsis
- Alzheimer's disease (AD) is a serious neurodegenerative disorder marked by amyloid-beta plaques and neurofibrillary tangles, and it's primarily initiated by the action of the enzyme BACE1 on amyloid precursor protein (APP).
- Researchers have discovered a small molecule that appears to effectively inhibit BACE1 by fitting well into its active site, outperforming the known drug Umibecestat (CNP-520) in terms of binding orientation and blocking the enzyme's activity.
- The study utilized advanced techniques like virtual high-throughput screening and molecular dynamics simulations to identify and analyze potential drug leads for AD treatment, ultimately suggesting a promising new inhibitor for further development.
Evaluation of Selected Plant Phenolics via Beta-Secretase-1 Inhibition, Molecular Docking, and Gene Expression Related to Alzheimer's Disease.
Pharmaceuticals (Basel)
October 2024
Department of Molecular Biology & Genetics, Faculty of Life & Natural Sciences, Abdullah Gül University, 38080 Kayseri, Türkiye.
The goal of the current study was to investigate the inhibitory activity of six phenolic compounds, i.e., rosmarinic acid, gallic acid, oleuropein, epigallocatechin gallate (EGCG), 3-hydroxytyrosol, and quercetin, against β-site amyloid precursor protein cleaving enzyme-1 (BACE1), also known as β-secretase or memapsin 2, which is implicated in the pathogenesis of Alzheimer's disease (AD).
View Article and Find Full Text PDFEffect of Functional Inhibition of BACE1 on Sensitization to γ-Irradiation in Cancer Cells.
Curr Issues Mol Biol
January 2024
Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan.
Developing strategies for the radiosensitization of cancer cells by the inhibition of genes, which harbor low toxicity to normal cells, will be useful for improving cancer radiotherapy. Here, we focused on a β-site of amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1; β-secretase, memapsin-2). By functional inhibition of this peptidase by siRNA, it has also recently been shown that the DNA strand break marker, γH2AX foci, increased, suggesting its involvement in DNA damage response.
View Article and Find Full Text PDFA Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
CNS Drugs
March 2019
Department of Neuroscience, Room E4032, UConn Health, 263 Farmington Avenue, Farmington, CT, 06030-3401, USA.
Alzheimer's disease (AD), the most common cause of age-dependent dementia, is one of the most significant healthcare problems worldwide. Aggravating this situation, drugs that are currently US Food and Drug Administration (FDA)-approved for AD treatment do not prevent or delay disease progression. Therefore, developing effective therapies for AD patients is of critical urgency.
View Article and Find Full Text PDFHighly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies.
ChemMedChem
March 2019
Department of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Herein we present the design, synthesis, and biological evaluation of potent and highly selective β-secretase 2 (memapsin 1, beta-site amyloid precursor protein cleaving enzyme 2, or BACE 2) inhibitors. BACE2 has been recognized as an exciting new target for type 2 diabetes. The X-ray structure of BACE1 bound to inhibitor 2 a {N -[(1S,2R)-1-benzyl-2-hydroxy-3-[[(1S,2S)-2-hydroxy-1-(isobutylcarbamoyl)propyl]amino]propyl]-5-[methyl(methylsulfonyl)amino]-N -[(1R)-1-phenylpropyl]benzene-1,3-dicarboxamide} containing a hydroxyethylamine isostere was determined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!